Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10

Journal of Natural Products

Volumn 74, Issue 5, 2011, Pages 962-968

  Pettit, George R ^a   Hogan, Fiona ^a   Toms, Steven ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOQUINOLINE; 4 AMINOQUINOLINE; 5 AMINOQUINOLINE; 6 AMINOQUINOLINE; 8 AMINOQUINOLINE; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AURISTATIN; DOLASTATIN 10; HYDROCORTISONE SODIUM PHOSPHATE; PHOSPHATE; QUINOLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOLABELLA AURICULA; DRUG EFFICACY; GASTROPOD; HUMAN; HUMAN CELL; LUNG CARCINOMA; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PROSTATE CARCINOMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA P388; MICE; MOLECULAR STRUCTURE;

ANASPIDEA; DOLABELLA AURICULARIA;

EID: 79957863775     PISSN: 01633864     EISSN: 15206025     Source Type: Journal    
DOI: 10.1021/np1007334     Document Type: Article

References (48)

1. For Antineoplastic Agents Part 591 refer to: Bai, R.; Nguyen, T. L.; Burnett, J. C.; Atasoylu, O.; Munro, M. H. G.; Pettit, G. R.; Smith, A. B., III; Gussio, R.; Hamel, E. J. Chem. Inf. Model., submitted.
2. (a) Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuinman, A. A.; Boettner, F. E.; Kizu, H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems, R. J. J. Am. Chem. Soc. 1987, 109, 6883-6885.
3. (b) Pettit, G. R. In Progress in the Chemistry of Organic Natural Products; Herz, W.; Kirby, G. W.; Moore, R. E.; Steglich, W.; Tamm, C., Eds.; Springer: Vienna, 1997; Vol. 70, pp 1-79.
4. (c) Pettit, G. R.; Srirangam, J. K.; Barkoczy, J.; Williams, M. D.; Durkin, K. P. M.; Boyd, M. R.; Bai, R.; Hamel, E.; Schmidt, J. M.; Chapuis, J.-C. Anti-Cancer Drug Des. 1995, 10, 529-544.
5. (d) Pettit, G. R.; Srirangam, J. K.; Barkoczy, J.; Williams, M. D.; Boyd, M. R.; Hamel, E.; Pettit, R. K.; Hogan, F.; Bai, R.; Chapuis, J.-C.; McAllister, S.; Schmidt, J. M. Anti-Cancer Drug Des. 1998, 13, 243-277.
6. Pettit, G. R. In International Oncology Updates: Marine Anticancer Compounds in the Era of Targeted Therapies; Chabner, B.; Cortés-Funes, H., Eds.; Permanyer Publications: Barcelona, 2009.
7. (a) Kobayashi, M.; Natsume, T.; Tamaoki, S.; Watanabe, J.; Asano, H.; Mikami, T.; Miyasaka, K.; Miyazaki, K.; Gondo, M.; Sakakibara, K.; Tsukagoshi, S. Jpn. J. Cancer Res. 1997, 88, 316-327.
8. (b) Fennell, B.; Carolan, S.; Pettit, G. R.; Bell, A. J. Antimicrob. Chemother. 2003, 51, 833-841.
9. (c) Watanabe, J.; Minami, M.; Kobayashi, M. Anticancer Res. 2006, 26, 1973-1981.
10. (d) Horti, J.; Juhasz, E.; Monostori, Z.; Maeda, K.; Eckhardt, S.; Bodrogi, I. Cancer Chemother. Pharmacol. 2008, 62, 173-180.
11. (e) Banerjee, S.; Wang, Z.; Mohammad, M.; Sarkar, F. H.; Mohammad, R. M. J. Nat. Prod. 2008, 71, 492-496.
12. Woyke, T.; Berens, M. E.; Hoelzinger, D. B.; Pettit, G. R.; Winkelmann, G.; Pettit, R. K. Antimicrob. Agents Chemother. 2004, 48, 561-567.
13. (a) Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; Chace, D. F.; DeBlanc, R. L.; Gearing, R. P.; Bovee, T. D.; Siegall, C. B.; Francisco, J. A.; Wahl, A. F.; Meyer, D. L.; Senter, P. D. Nat. Biotechnol. 2003, 21, 778-784.
14. (b) Temming, K.; Mayer, D. L.; Zabinski, R.; Dijkers, E. C. F.; Poelstra, K.; Molema, G.; Kok, R. J. Bioconjugate Chem. 2006, 17, 1385-1394.
15. (c) Temming, K.; Meyer, D. L.; Zabinski, R.; Senter, P. D.; Poelstra, K.; Molema, G.; Kok, R. J. Mol. Pharmaceut. 2007, 4, 686-694.
16. Shnyder, S. D.; Cooper, P. A.; Millington, N. J.; Pettit, G. R.; Bibby, M. C. Int. J. Oncol. 2007, 31, 353-360.
17. (a) Pettit, G. R.; Lippert, J. W., III. Anti-Cancer Drug Des. 2000, 15, 203-216.
18. (b) Kirwan, I. G.; Loadman, P. M.; Swaine, D. J.; Anthoney, D. A.; Pettit, G. R.; Lippert, J. W., III; Shnyder, S. D.; Cooper, P. A.; Bibby, M. C. Clin. Cancer Res. 2004, 10, 1446-1453.
19. (c) Hokland, S. L.; Horsman, M. R. Int. J. Hypothermia 2007, 23, 599-606.
20. (d) Dalal, S.; Burchill, S. A. Eur. J. Cancer 2009, 45, 713-722.
21. (a) Pettit, G. R.; Rhodes, M. R. Anti-Cancer Drug Des. 1998, 13, 183-191.
22. (b) Patterson, D. M.; Rustin, G. J. S.; Serradell, N.; Rosa, E.; Bolos, J. Drugs Future 2007, 32, 1025-1032.
23. Pettit, G. R.; Melody, N.; Herald, D. L. J. Nat. Prod. 2004, 67, 322-327.
24. Mamber, S. W.; Mikkilineni, A. B.; Pack, E. J.; Rosser, M. P.; Wong, H.; Ueda, Y.; Forenza, S. J. Pharm. Exp. Ther. 1995, 274, 877-883.
25. Saulnier, M. G.; Langley, D. R.; Kadow, J. F.; Senter, P. D.; Knipe, J. O.; Tun, M. M.; Vyas, D. M.; Doyle, T. W. Bioorg. Med. Chem. Lett. 1994, 4, 2567-2572.
26. (a) Egan, T. J.; Hunter, R.; Kaschula, C. H.; Marques, H. M.; Misplon, A.;Walden, J. J. Med. Chem. 2000, 43, 283-291.
27. (b) Nanayakkara, N. P. D.; Ager, A. L., Jr.; Bartlett, M. S.; Yardley, V.; Croft, S. L.; Khan, I. A.; McChesney, J. D.; Walker, L. A. Antimicrob. Agents Chemother. 2008, 52, 2130-2137.
28. (c) Vale, N.; Moreira, R.; Gomes, P. Eur. J. Med. Chem. 2009, 44, 937-953.
29. (d) Kouznetsov, V. V.; Gómez-Barrio, A. Eur. J. Med. Chem. 2009, 44, 3091-3113.
30. (a) Pfister, J. R. J. Nat. Prod. 1988, 51, 969-970.
31. (b) Sheridan, R. E.; Deshpande, S. S.; Nicholson, J. D.; Adler, M. Toxicon 1997, 35, 1439-1451.
32. (c) Beresnevicius, Z. J.; Viliunas, V.; Kantminiene, K. Chem. Heterocycl. Compd. (Khim. Geterotsikl. Soedin.) 2000, 36, 432-438.
33. (d) Goda, F. E.; Abdel-Aziz, A. A.-M.; Ghoneim, H. A. Bioorg. Med. Chem. 2005, 13, 3175-3183.
34. (e) Shao, Y.; Zhang, J.; Tu, C.; Dai, C.; Xu, Q.; Guo, Z. J. Inorg. Chem. 2005, 99, 1490-1496.
35. (f) DeVita, R. J. Curr. Top. Med. Chem. 2007, 7, 1433-1439.
36. (a) Pettit, G. R.; Singh, S. B.; Herald, D. L.; Lloyd-Williams, P.; Kantoci, D.; Burkett, D. D.; Barkóczy, J.; Hogan, F.; Wardlaw, T. R. J. Org. Chem. 1994, 59, 6287-6295.
37. (b) Pettit, G. R.; Grealish, M. P. J. Org. Chem. 2001, 66, 8640-8642.
38. (c) Mordant, C.; Reymond, S.; Tone, H.; Lavergne, D.; Touati, R.; Ben Hassine, B.; Ratovelomanana-Vidal, V; Genet, J.-P. Tetrahedron 2007, 63, 6115-6123.
39. Pettit, G. R.; Srirangam, J. K.; Singh, S. B.; Williams, M. D.; Herald, D. L.; Barkóczy, J.; Kantoci, D.; Hogan, F. J. Chem. Soc., Perkin Trans. 1 1996, 859-863.
40. (a) Schulman, S. G.; Abate, K.; Kovi, P. J.; Capomacchia, A. C.; Jackman, D. Anal. Chim. Acta 1973, 65, 59-67.
41. (b) Abernethy, J. L.; Kilday, W. J. Org. Chem. 1960, 25, 1924-1928.
42. (a) Pozdnev, V. F. Int. J. Peptide Protein Res. 1994, 36-48.
43. (b) Furlong, S. T.; Mauger, R. C.; Strimpler, A. M.; Liu, Y.-P.; Morris, F. X.; Edwards, P. D. Bioorg. Med. Chem. 2002, 10, 3637-3647.
44. (a) Olah, G. A.; Nojima, M.; Kerekes, I. Synthesis 1973, 487-488.
45. (b) Bertho, J.-N.; Loffet, A.; Pinel, C.; Reuther, F.; Sennyey, G. Tetrahedron Lett. 1991, 32, 1303-1306.
46. (a) Carpino, L. A.; Mansour, E.-S. M. E.; Sadat-Aalee, D. J. Org. Chem. 1991, 56, 2611-2614.
47. (b) Wenschuh, H.; Beyermann, M.; El-Faham, A.; Ghassemi, S.; Carpino, L. A.; Bienert, M. J. Chem. Soc., Chem. Commun. 1995, 669-670.
48. (c) Carpino, L. A.; Beyermann, M.; Wenschuh, H.; Bienert, M. Acc. Chem. Res. 1996, 29, 268-274.